|Table of Contents|
Apixaban – another new oral anticoagulant on the horizon for atrial fibrillation
Published in : HAMDAN MEDICAL JOURNAL ; Vol 5, No 1 (2012)
DOI : 10.7707/hmj.v5i1.109
Anticoagulation of patients with atrial fibrillation iscrucial to prevent thromboembolic events. However,the currently used vitamin K antagonists (VKAs) havesevere disadvantages, such as an increased risk ofintracerebral bleeding or the necessity of laboratorymonitoring. Recently, new oral anticoagulants directlyinhibiting factor Xa or thrombin have been testedwhich may overcome these drawbacks. In 2011 the ARISTOTL E study testing the oral direct factor Xainhibitor apixaban was published in the New EnglandJournal of Medicine (http://www.nejm.org/doi/full/10.1056/NEJMoa1107039).